First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis.

Trial Profile

First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Anti-interleukin-21 monoclonal antibody (Primary) ; Anti-interleukin-21 monoclonal antibody (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Feb 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top